1323 related articles for article (PubMed ID: 18420099)
1. Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia.
Guyton JR; Brown BG; Fazio S; Polis A; Tomassini JE; Tershakovec AM
J Am Coll Cardiol; 2008 Apr; 51(16):1564-72. PubMed ID: 18420099
[TBL] [Abstract][Full Text] [Related]
2. Long-term safety and efficacy of triple combination ezetimibe/simvastatin plus extended-release niacin in patients with hyperlipidemia.
Fazio S; Guyton JR; Polis AB; Adewale AJ; Tomassini JE; Ryan NW; Tershakovec AM
Am J Cardiol; 2010 Feb; 105(4):487-94. PubMed ID: 20152243
[TBL] [Abstract][Full Text] [Related]
3. Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients.
Catapano AL; Davidson MH; Ballantyne CM; Brady WE; Gazzara RA; Tomassini JE; Tershakovec AM
Curr Med Res Opin; 2006 Oct; 22(10):2041-53. PubMed ID: 17022864
[TBL] [Abstract][Full Text] [Related]
4. A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia.
Bays HE; Ose L; Fraser N; Tribble DL; Quinto K; Reyes R; Johnson-Levonas AO; Sapre A; Donahue SR;
Clin Ther; 2004 Nov; 26(11):1758-73. PubMed ID: 15639688
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the lipid-modifying efficacy and safety profiles of ezetimibe coadministered with simvastatin in older versus younger patients with primary hypercholesterolemia: a post Hoc analysis of subpopulations from three pooled clinical trials.
Feldman T; Davidson M; Shah A; Maccubbin D; Meehan A; Zakson M; Tribble D; Veltri E; Mitchel Y
Clin Ther; 2006 Jun; 28(6):849-59. PubMed ID: 16860168
[TBL] [Abstract][Full Text] [Related]
6. Consistency of lipid-altering effects of ezetimibe/simvastatin across gender, race, age, baseline low density lipoprotein cholesterol levels, and coronary heart disease status: results of a pooled retrospective analysis.
Ose L; Shah A; Davies MJ; Rotonda J; Maccubbin D; Tribble D; Veltri E; Mitchel Y
Curr Med Res Opin; 2006 May; 22(5):823-35. PubMed ID: 16709304
[TBL] [Abstract][Full Text] [Related]
7. Long-term safety and, tolerability profiles and lipid-modifying efficacy of ezetimibe coadministered with ongoing simvastatin treatment: a multicenter, randomized, double-blind, placebo-controlled, 48-week extension study.
Masana L; Mata P; Gagné C; Sirah W; Cho M; Johnson-Levonas AO; Meehan A; Troxell JK; Gumbiner B;
Clin Ther; 2005 Feb; 27(2):174-84. PubMed ID: 15811480
[TBL] [Abstract][Full Text] [Related]
8. Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized, open-label, parallel-group study.
Alvarez-Sala LA; Cachofeiro V; Masana L; Suarez C; Pinilla B; Plana N; Trias F; Moreno MA; Gambus G; Lahera V; Pintó X
Clin Ther; 2008 Jan; 30(1):84-97. PubMed ID: 18343245
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs simvastatin monotherapy in patients with increased non-HDL cholesterol (from the SEACOAST I study).
Ballantyne CM; Davidson MH; McKenney J; Keller LH; Bajorunas DR; Karas RH
Am J Cardiol; 2008 May; 101(10):1428-36. PubMed ID: 18471454
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low-density lipoprotein cholesterol goals in older and elderly patients: subanalyses of data from a randomized, double-blind, placebo-controlled trial.
Pearson T; Denke M; McBride P; Battisti WP; Brady WE; Palmisano J
Am J Geriatr Pharmacother; 2005 Dec; 3(4):218-28. PubMed ID: 16503317
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of combination of extended release niacin and atorvastatin in patients with low levels of high density lipoprotein cholesterol.
Harikrishnan S; Rajeev E; Tharakan JA; Titus T; Ajit Kumar VK; Sivasankaran S; Krishnamoorthy KM; Nair K
Indian Heart J; 2008; 60(3):215-22. PubMed ID: 19240310
[TBL] [Abstract][Full Text] [Related]
12. Lipid-lowering effects of colesevelam HCl in combination with ezetimibe.
Bays H; Rhyne J; Abby S; Lai YL; Jones M
Curr Med Res Opin; 2006 Nov; 22(11):2191-200. PubMed ID: 17076980
[TBL] [Abstract][Full Text] [Related]
13. Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) study.
Ballantyne CM; Abate N; Yuan Z; King TR; Palmisano J
Am Heart J; 2005 Mar; 149(3):464-73. PubMed ID: 15864235
[TBL] [Abstract][Full Text] [Related]
14. Consistency in efficacy and safety of ezetimibe coadministered with statins for treatment of hypercholesterolemia in women and men.
Bennett S; Sager P; Lipka L; Melani L; Suresh R; Veltri E;
J Womens Health (Larchmt); 2004 Dec; 13(10):1101-7. PubMed ID: 15650343
[TBL] [Abstract][Full Text] [Related]
15. Effects of ezetimibe/simvastatin on lipoprotein subfractions in patients with primary hypercholesterolemia: an exploratory analysis of archived samples using two commercially available techniques.
Ose L; Reyes R; Johnson-Levonas AO; Sapre A; Tribble DL; Musliner T
Clin Ther; 2007 Nov; 29(11):2419-32. PubMed ID: 18158082
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of ezetimibe/simvastatin combination versus atorvastatin alone in adults ≥65 years of age with hypercholesterolemia and with or at moderately high/high risk for coronary heart disease (the VYTELD study).
Foody JM; Brown WV; Zieve F; Adewale AJ; Flaim D; Lowe RS; Jones-Burton C; Tershakovec AM
Am J Cardiol; 2010 Nov; 106(9):1255-63. PubMed ID: 21029821
[TBL] [Abstract][Full Text] [Related]
17. Tolerability and effects on lipids of ezetimibe coadministered with pravastatin or simvastatin for twelve months: results from two open-label extension studies in hypercholesterolemic patients.
Strony J; Hoffman R; Hanson M; Veltri E
Clin Ther; 2008 Dec; 30(12):2280-97. PubMed ID: 19167588
[TBL] [Abstract][Full Text] [Related]
18. Lipid-altering efficacy of switching from atorvastatin 10 mg/day to ezetimibe/simvastatin 10/20 mg/day compared to doubling the dose of atorvastatin in hypercholesterolaemic patients with atherosclerosis or coronary heart disease.
Barrios V; Amabile N; Paganelli F; Chen JW; Allen C; Johnson-Levonas AO; Massaad R; Vandormael K
Int J Clin Pract; 2005 Dec; 59(12):1377-86. PubMed ID: 16351668
[TBL] [Abstract][Full Text] [Related]
19. Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial.
Derosa G; Cicero AE; Bertone G; Piccinni MN; Ciccarelli L; Roggeri DE
Clin Ther; 2004 Oct; 26(10):1599-607. PubMed ID: 15598476
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of coadministration of ezetimibe and simvastatin in adolescents with heterozygous familial hypercholesterolemia.
van der Graaf A; Cuffie-Jackson C; Vissers MN; Trip MD; Gagné C; Shi G; Veltri E; Avis HJ; Kastelein JJ
J Am Coll Cardiol; 2008 Oct; 52(17):1421-9. PubMed ID: 18940534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]